Impedimed Limited
(ASX:IPD) says it has secured another NCI designated cancer centre for the post approval trial of its L-Dex device.
The L-Dex technology helps physicians and surgeon detect changes in cellular fluid levels to detect lymphedema post-surgery.
The trial has been gaining momentum with the procedure also recently gaining reimbursement classification. The medical device is also the first of its kind with FDA clearance in the US.
Impedimed reported a net loss of $6.1 million for the full year ending 31 December 2014.
